Mikhail M, et al. - Authors ascertained if the presence of vitreomacular interface abnormalities (VMIA) in patients with diabetic macular oedema (DMO) modified the response to ranibizumab. They included 146 eyes of 100 patients (mean age 63.5 years) followed for a mean of 9 months (range 2–14 months; only 9/146 dropped to follow-up before month 6). In patients with DMO, an association of VMIA with worse presenting vision was seen. In this study, the response to ranibizumab was not modified by VMIA or change in the posterior hyaloid face during the follow-up.